ADIL
Income statement / Annual
Last year (2025), Adial Pharmaceuticals Inc's total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Adial Pharmaceuticals Inc's net income was -$7.98 M.
See Adial Pharmaceuticals Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$564.00
|
$0.00
|
$0.00
|
$564.00
|
$565.00
|
$563.00
|
$565.00
|
$565.00
|
| Gross Profit |
$0.00
|
$0.00
|
-$564.00
|
$0.00
|
$0.00
|
-$564.00
|
-$565.00
|
-$563.00
|
-$565.00
|
-$565.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$2.62 M
|
$3.23 M
|
$1.27 M
|
$1.95 M
|
$8.40 M
|
$5.85 M
|
$3.97 M
|
$368.46 K
|
$182.11 K
|
$146.14 K
|
| General & Administrative Expenses |
$5.18 M
|
$5.06 M
|
$5.62 M
|
$8.91 M
|
$9.34 M
|
$5.07 M
|
$4.28 M
|
$6.62 M
|
$813.18 K
|
$264.66 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.18 M
|
$5.06 M
|
$5.62 M
|
$8.91 M
|
$9.34 M
|
$5.07 M
|
$4.28 M
|
$6.62 M
|
$813.18 K
|
$264.66 K
|
| Other Expenses |
$0.00
|
$0.00
|
-$564.00
|
$0.00
|
$1.55 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$7.80 M
|
$8.28 M
|
$6.89 M
|
$10.86 M
|
$19.29 M
|
$10.93 M
|
$8.24 M
|
$6.99 M
|
$995.29 K
|
$410.81 K
|
| Cost And Expenses |
$7.80 M
|
$8.28 M
|
$6.89 M
|
$10.86 M
|
$19.29 M
|
$10.93 M
|
$8.24 M
|
$6.99 M
|
$995.29 K
|
$410.81 K
|
| Interest Income |
$149.57 K
|
$178.66 K
|
$69.78 K
|
$63.34 K
|
$6.54 K
|
$32.50 K
|
$95.23 K
|
$7.39 K
|
$367.00
|
$240.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.17 M
|
$144.54 K
|
$9.64 K
|
| Depreciation & Amortization |
$565.00
|
$565.00
|
$564.00
|
$564.00
|
$55.11 K
|
$564.00
|
$565.00
|
$563.00
|
$565.00
|
$565.00
|
| EBITDA |
-$7.80 M |
-$8.28 M |
-$7.00 M |
-$10.86 M |
-$17.69 M |
-$10.93 M |
-$8.59 M |
-$6.98 M |
-$994.35 K |
-$410.00 K |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$177.71 K
|
-$4.91 M
|
-$113.94 K
|
$63.34 K
|
-$228.68 K
|
$35.00 K
|
-$346.53 K
|
-$4.64 M
|
-$144.17 K
|
-$9.39 K
|
| Income Before Tax |
-$7.98 M
|
-$13.20 M
|
-$7.00 M
|
-$10.80 M
|
-$19.52 M
|
-$10.89 M
|
-$8.59 M
|
-$11.63 M
|
-$1.14 M
|
-$420.20 K
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$94.08 K
|
-$32.50 K
|
$0.00
|
$0.00
|
$367.00
|
$0.00
|
| Net Income |
-$7.98 M
|
-$13.20 M
|
-$7.00 M
|
-$12.73 M
|
-$19.42 M
|
-$10.86 M
|
-$8.59 M
|
-$11.63 M
|
-$1.14 M
|
-$420.20 K
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-11.93 |
-17.75 |
-136 |
-299.5 |
-653 |
-544.75 |
-545 |
-1527.5 |
-130 |
-55 |
| EPS Diluted |
-11.93 |
-17.75 |
-136 |
-299.5 |
-653 |
-544.75 |
-545 |
-1527.5 |
-130 |
-55 |
| Weighted Average Shares Out |
$668.63 K
|
$743.55 K
|
$56.99 K
|
$42.52 K
|
$29.74 K
|
$19.94 K
|
$15.76 K
|
$7.62 K
|
$8.76 K
|
$7.65 K
|
| Weighted Average Shares Out Diluted |
$668.63 K
|
$743.55 K
|
$56.99 K
|
$42.52 K
|
$29.74 K
|
$19.94 K
|
$15.76 K
|
$7.62 K
|
$8.76 K
|
$7.65 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
